Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORA-4: Lisaftoclax (APG-2575) + Azacitidine vs Azacitidine in Newly Diagnosed Higher-Risk MDS
jRCT2041260051Phase 3Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Lisaftoclax + Azacitidine with Azacitidine + Placebo (2 arms). Primary endpoint: Overall survival. Started Jun 2026; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2041260051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260051.